Beigene, Ltd. (NASDAQ:ONC - Get Free Report) CEO John Oyler sold 5,127 shares of the stock in a transaction on Friday, June 6th. The stock was sold at an average price of $252.77, for a total value of $1,295,951.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Beigene Stock Down 2.5%
ONC stock traded down $6.90 during trading on Friday, reaching $269.63. 391,727 shares of the company's stock were exchanged, compared to its average volume of 451,056. The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05. Beigene, Ltd. has a 1-year low of $141.31 and a 1-year high of $287.88. The company has a fifty day simple moving average of $240.18. The stock has a market capitalization of $31.92 billion, a price-to-earnings ratio of -32.72, a PEG ratio of 7.73 and a beta of 0.30.
Beigene (NASDAQ:ONC - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.71) by $1.93. The company had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.12 billion. Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. As a group, sell-side analysts expect that Beigene, Ltd. will post -5.82 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of analysts have issued reports on ONC shares. TD Securities reissued a "buy" rating and issued a $334.00 price target on shares of Beigene in a research note on Thursday, April 24th. Royal Bank of Canada dropped their target price on Beigene from $312.00 to $311.00 and set an "outperform" rating on the stock in a report on Thursday, May 8th. JMP Securities set a $348.00 target price on Beigene in a report on Friday, February 28th. Guggenheim lifted their price objective on Beigene from $348.00 to $350.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Finally, Wall Street Zen upgraded Beigene from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Beigene currently has an average rating of "Buy" and an average target price of $319.00.
Get Our Latest Stock Report on Beigene
Beigene Company Profile
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.
Further Reading
Before you consider BeOne Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeOne Medicines wasn't on the list.
While BeOne Medicines currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
